Latest Breaking News On - ப்ரீஶியந்ஸ் பாயஂட் - Page 1 : comparemela.com

MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders

Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX’s Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner Entirely Reconstituted Board and New Management Team Positioned Company for Long-Term Sustainable Growth; Stock Price Appreciation of 237% Since Timothy Wright Selected as CEO Virtual Annual Meeting to Be Held on May 27, 2021 MARIETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with its 2021 Annual Meeting of Shareholders (“Annual Meeting”), to be held virtually on May 27, 2021 at 10:00 a.m. Eastern Time at www.cesonlineservices.com/mdxg21 vm. MIMEDX shareholders of record at as of 5:00 p.m. Eastern Time on April 16, 20

MIMEDX Files Definitive Proxy Materials and Mails Letter to

MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders May 03, 2021 08:02 ET | Source: MiMedx Group, Inc MiMedx Group, Inc Marietta, Georgia, UNITED STATES Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX’s Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner Entirely Reconstituted Board and New Management Team Positioned Company for Long-Term Sustainable Growth; Stock Price Appreciation of 237% Since Timothy Wright Selected as CEO Virtual Annual Meeting to Be Held on May 27, 2021 MARIETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it has filed definitive proxy mat

Prescience Point Capital Management to Nominate Four Highly Qualified Director Candidates to MiMedx Board at 2021 Annual Meeting

Prescience Point Capital Management to Nominate Four Highly Qualified Director Candidates to MiMedx Board at 2021 Annual Meeting Sends Letter to Fellow MiMedx Shareholders Citing Board s Failure to Maximize Shareholder Value News provided by Share this article Share this article BATON ROUGE, La., April 16, 2021 /PRNewswire/  Prescience Point Capital Management, together with its affiliates ( Prescience Point ), a research-focused, catalyst-driven investment firm, announced today the nomination of four highly qualified director candidates to the Board of Directors (the Board ) of MiMedx Group, Inc. (NASDAQ: MDXG) ( MiMedx or the Company ). Prescience Point, a beneficial owner of approximately 8.1% of the outstanding shares of MiMedx, believes that the best path forward for unlocking shareholder value is the addition of Mr. Eiad Asbahi, Mr. Alfred G. Merriweather, Ms. Charlotte E. Sibley, and Mr. William F. Spengler to the Board at the upcoming Annual Meeting of Shareholders

Prescience Point Capital Management Raises Price Target on MiMedx Group to $31 Per Share

Prescience Point Capital Management Raises Price Target on MiMedx Group to $31 Per Share New Research Indicates That MiMedx s Amniofix Injectable Product Will Be A Blockbuster, Game-Changing Treatment for Knee Osteoarthritis MiMedx s Wound Care Sales Are Poised To Re-Accelerate Over The Coming Quarters Due To Recent Contract And Insurance Wins And A New Product Launch News provided by Share this article Share this article BATON ROUGE, La., Dec. 16, 2020 /PRNewswire/  Prescience Point Capital Management, a research-focused, catalyst-driven investment firm, today announced it has issued new research on MiMedx Group Inc. (Nasdaq: MDXG), raising the price target on the leading advanced wound care and therapeutic biologics company to $31 per share. Prescience Point is one of the company s largest shareholders, owning 9 million or approximately 6.5% of the fully-diluted common stock of MiMedx.

MiMedx: Raising Our PT To $31 On New Findings That Indicate Amniofix Will Be A Blockbuster, Game-Changing Osteoarthritis Treatment (NASDAQ:MDXG)